Astrana Health, Inc. (NASDAQ:ASTH) Sees Significant Decrease in Short Interest

Astrana Health, Inc. (NASDAQ:ASTH) was the recipient of a significant drop in short interest in January. As of January 15th, there was short interest totalling 1,490,000 shares, a drop of 8.6% from the December 31st total of 1,630,000 shares. Based on an average daily trading volume, of 303,600 shares, the short-interest ratio is presently 4.9 days. Approximately 4.2% of the shares of the stock are sold short.

Hedge Funds Weigh In On Astrana Health

Institutional investors and hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC bought a new stake in Astrana Health in the 3rd quarter valued at about $34,000. Nisa Investment Advisors LLC acquired a new stake in shares of Astrana Health in the 3rd quarter valued at approximately $35,000. KBC Group NV bought a new stake in shares of Astrana Health during the third quarter worth $70,000. Quarry LP bought a new stake in Astrana Health during the 3rd quarter worth $77,000. Finally, Quest Partners LLC acquired a new position in shares of Astrana Health in the third quarter valued at approximately $133,000. 52.77% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ASTH has been the topic of several analyst reports. Truist Financial dropped their target price on shares of Astrana Health from $59.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, January 13th. KeyCorp assumed coverage on Astrana Health in a research note on Friday, October 11th. They set a “sector weight” rating for the company. Macquarie raised shares of Astrana Health to a “hold” rating in a research note on Monday, December 16th. TD Cowen began coverage on Astrana Health in a research report on Monday, October 14th. They set a “buy” rating and a $66.00 target price for the company. Finally, Robert W. Baird raised their price objective on shares of Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Astrana Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $63.67.

Astrana Health Stock Up 0.2 %

Shares of Astrana Health stock traded up $0.09 on Monday, hitting $36.96. The company had a trading volume of 100,769 shares, compared to its average volume of 379,222. The stock has a 50-day moving average of $36.27 and a 200-day moving average of $46.31. The firm has a market capitalization of $2.08 billion, a P/E ratio of 28.37, a P/E/G ratio of 1.42 and a beta of 1.20. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. Astrana Health has a twelve month low of $29.08 and a twelve month high of $63.20.

Astrana Health (NASDAQ:ASTH) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.33 EPS for the quarter, hitting the consensus estimate of $0.33. The firm had revenue of $478.71 million for the quarter, compared to analysts’ expectations of $462.01 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. During the same period in the previous year, the firm posted $0.47 EPS. Research analysts predict that Astrana Health will post 1.15 earnings per share for the current year.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.